Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer

Erin M. Dickey; Anna Bianchi; Haleh Amirian; Peter J. Hosein; Denise Faustman; Roberta Brambilla; Jashodeep Datta

doi:10.1080/2162402X.2024.2326694

OncoImmunology (Dec 2024)

Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer

Erin M. Dickey,
Anna Bianchi,
Haleh Amirian,
Peter J. Hosein,
Denise Faustman,
Roberta Brambilla,
Jashodeep Datta

Affiliations

Erin M. Dickey: Division of Surgical Oncology, DeWitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
Anna Bianchi: Division of Surgical Oncology, DeWitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
Haleh Amirian: Division of Surgical Oncology, DeWitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
Peter J. Hosein: Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
Denise Faustman: Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Roberta Brambilla: The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
Jashodeep Datta: Division of Surgical Oncology, DeWitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA

DOI: https://doi.org/10.1080/2162402X.2024.2326694
Journal volume & issue: Vol. 13, no. 1

Abstract

Read online

Pancreatic cancer is characterized by extreme therapeutic resistance. In pancreatic cancers harboring high-risk genomes, we describe that cancer cell-neutrophil signaling circuitry provokes neutrophil-derived transmembrane (tm)TNF-TNFR2 interactions that dictate inflammatory polarization in cancer-associated fibroblasts and T-cell dysfunction – two hallmarks of therapeutic resistance. Targeting tmTNF-TNFR2 signaling may sensitize pancreatic cancer to chemo±immunotherapy.

Published in OncoImmunology

ISSN: 2162-402X (Online)
Publisher: Taylor & Francis Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.tandfonline.com/journals/koni

About the journal

Abstract

Keywords